Skin tumors in mice force Protagonist to halt lead program, crushing stock

Protagonist Therapeutics just can’t catch a break. Six months after the Newark, CA-based biotech unveiled grand plans to launch its lead candidate for blood disorders into a Phase III trial, the FDA has slapped the program with a clinical hold. The halt — which applies to all trials involving the…

...

Click to view original post